On August 7, ResMed fell 5.03% in after-hours trading, trading at approximately $212.0 per share, with turnover of $2.46 million. The decline came immediately after the company reported Q4 fiscal year results that slightly exceeded expectations but signaled a moderation in growth momentum.

ResMed posted Q4 adjusted earnings of $2.95 per diluted share, above the $2.89 analyst consensus, and revenue of $1.46 billion versus $1.35 billion a year ago, matching expectations. Simultaneously, the company announced plans to return over $1.85 billion to shareholders in fiscal year 2027 and raised its quarterly dividend 10% to $0.66 per share. However, revenue growth of approximately 8% year-over-year marked a deceleration from the roughly 10% growth in the prior quarter, fueling investor concerns about slowing momentum.

The sell-off follows a period of mounting headwinds, including Morgan Stanley's downgrade citing GLP-1 weight-loss drug competition and rival device market re-entry, as well as multiple analyst price target reductions in recent months. The consensus target has declined from above $300 to approximately $263.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)